





2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan

PLANNING SESSION ON IMPLEMENTATION OF APEC THIRD PARTY GUIDANCE (18 JULY) MEDICAL DEVICE SECTOR



Introductory Remarks

Ms. Tricia Van Orden, Project Overseer Business Ethics for APEC SMEs Initiative U.S. Department of Commerce



PLANNING SESSION ON IMPLEMENTATION OF APEC THIRD PARTY GUIDANCE (18 JULY) MEDICAL DEVICE SECTOR

Participant Introductions

NAME | POSITION | ORGANIZATION | ECONOMY



PLANNING SESSION ON IMPLEMENTATION OF APEC THIRD PARTY GUIDANCE (18 JULY) MEDICAL DEVICE SECTOR



Scene Setting Presentation

Ms. Faye Sumner MTANZ (New Zealand)



Defining Third Party Sales and Marketing Intermediaries

Large, medium, and small-sized enterprises that contract with medical device researchers and manufacturers ("medical device companies") in support of their business activities.

Third party intermediaries can include: distributors, wholesalers, distribution or sales agents, marketing agents or consultants, brokers, commission agents, and independent sales representatives.

Any enterprise that is paid by medical device companies in support of their business activities can be a third party intermediary. Especially if the enterprise is being paid by the company and interacting with external entities (governments, HCPs, hospitals, etc.)



Examples of Third Party Intermediary Risks in the APEC Region

- The absence of a medical device company having an anti-bribery policy in place and/or the third party intermediary engaging in an act of bribery to advance their business mission with the company.
- Incomplete / outdated collection and retention policies on financial transactions as well as external engagements.
- Low threshold by the company as well as the third party on what is an acceptable activity when engaging with external entities.
- Unusual arrangements or the absence of a written / routinely reviewed contract with a clear anti-corruption focus.



Industry's Early Response

- This is an ethics issue that extends to every industry and economy
- Large, Multi-National Companies
- Early Industry Association Focus
 - MTAA & MTANZ
 - AdavMed
 - MedTech Euorpe
- Role of the U.S. FCPA and U.K. Anti-Bribery Act



Building International Industry Association Collaboration

In 2014, the medical device industry achieved a milestone that no other sector has done: jointly shared, multi-national guidance on high-standard ethical business practices for third parties:

Australia (MTAA)

Canada (MEDEC)

European Union (MedTech Europe)

New Zealand (MTANZ)

United States (AdvaMed)



Breakthrough of the APEC Guidance / Expert Working Group

- Building on the joint industry association guidance by four APEC economies, the opportunity for APEC guidance was raised at the 2016 APEC Business Ethics for SMEs Forum in Lima.
- It was recommended by the plenary in Lima for the overseer to form an Expert Working Group to prepare draft APEC Guidance. This was completed virtually, on a multi-economy and multi-stakeholder, with the draft Guidance prepared for the 2017 APEC Business Ethics for SMEs Forum in Hanoi.
- The Guidance was reviewed and updated by the plenary in Hanoi, recommended to the overseer for submission to the APEC SME Working Group and 2017 APEC SME Ministerial.



2017 APEC SME Ministerial Statement

Ho Chi Minh City, Viet Nam (15 September 2017)

We welcome the APEC Guidance for Ethical Third Party Intermediary Relationships in the Medical Device Sector and encouraged its implementation. This Guidance serves as a concrete tool to support thousands of SMEs who play a critical role in the medical device sector, such as distributors, wholesalers and sales agents.



What the Guidance Says, In Short...

- First inter-governmental, international guidance to encourage ethical third party relationships in the medical device sector.
- Guidance applies equally to companies and third parties.
- Embraces APEC Kuala Lumpur Principles implementation
- Seven key sections: Written Anti-Bribery Policy / Procedure, Risk Assessment, Diligence Program, Written Contract, Training and Education, Monitor/Audit, Appropriate Corrective Action.
- Implementation Provisions (Foundation to Tokyo Statement)



What the Guidance Says, In Short...

Implementation Provisions (Foundation to Tokyo Statement)

- Multi-Stakeholder cooperation is a necessity
- $\,\circ\,$ Implementation of consistent codes of ethics
- Development and implementation of high-standard, aligned policies
- Encourage regulators and enforcement authorities to acknowledge and support the success of this guidance
- Economies to advance ethical collaborations through regular communication, joint policies and capacity-building



Our Four Morning Tasks:

- 1. Patricia Wu to overview APEC virtual capacity-building planning and developments since the Guidance was launched
- 2. Mexico, Japan, and Brazil perspective on local ethics trainings programs to-date for third party intermediaries
- 3. Outcomes from APEC Guidance pilot webinar in New Zealand and Canada by Chrisoula Nikidis (Polaris)
- 4. Inputs from delegates on the Tokyo Statement



TAKING STOCK: OVERVIEW OF IMPLEMENTATION RESOURCES



Ms. Patricia Wu Managing Director C&M International (Technical Secretariat)

http://klprinciples.apec.org/view.asp?ccid=471



CAPACITY BUILDING EXAMPLES: DISTRIBUTOR ETHICS TRAININGS



Recent Association Approaches

Ms. Tamara Olmos AMID (Mexico)



2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan



Is conformed by 32 multinational companies, all manufacturers



2013 Code of Interaction w/ HCP´s		2017 Review alignment w/ Bogota Principles	TIMETABLE	2018 January prohibition - Direct sponsorship -E & R places		
	2016 Review of Code of Interaction w/ HCP´s		2017 New Code was published. Is also mandatory for distributors by contract		2018 January Sanctions procedure	



HOW DID WE IMPLEMENTED OUR CODE?





TRAININGS DONE & OUR EXPERIENCE





LESSONS LEARNED / RECOMMENDATIONS Affiliates/distributors may say: What to do: Main tool: train affiliates first & distributors to make They do not know the AMID's Code them aware of the Code's provisions They have commitments prior the effectiveness of the Provide a time-period for implementation of New Code Code Sensitize all affiliates on the importance of the Tone Is how business is done in the Country from the Top with distributors to set an example During the training distributors sign Compliance Codes and/or rules only apply for direct Affiliates Certification They lost, forgot, or did not understand the information Facilitate Marketing in social media given



2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan

CHALLENGES

Distributors are not part of AMID therefore we cannot force them directly to comply In Mexico we have many family owned companies that do not have the size/budget to have a Compliance officer

High index of corruption in the country



2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan

WHAT IS IN THE FUTURE?

Strategic alliance with UN to learn from their experience

Strategic alliances w/other Association (including distributors) Encourage the formalization of contracts with all types of channel of distribution

+ trainings to distributors at cities within the Country



CAPACITY BUILDING EXAMPLES: DISTRIBUTOR ETHICS TRAININGS



Recent Association Approaches

Koichiro Miyata AMDD (Japan)



- Capacity-Building Examples on Distributors Ethics Trainings -

AMDD-organized Anti-corruption training to dealers

Efforts to help delivering the training efficiently and effectively

July 18, 2018 Koichiro Miyata Legal & Compliance Committee

AMDD



AMDD

- Date of Establishment:
- # of Member Companies:
- # of Employees:
- Total Sales of member Cos. :

April 1, 2009 63 (as of Feb 2018)

26,000

1.8 trillion yen (67% of Japanese Market)

<Mission Statement>

Enabling a healthier Japan <u>Providing valuable medical technology and information to</u> your loved ones today, so that they may live in good health.







- Overview
 - Program scheme:
 - AMDD organizes and delivers trainings
 - Sponsoring member companies endorse AMDD training as their own training and certify dealers who took the training
 - Program Launch: 2012
 - Frequency: Once a year (every November)
 - Venue: 7 major cities across Japan
 - Length of training: 2 hrs.
 - Speaker: Licensed lawyer (Bengoshi) from an outside law firm
 - # of sponsoring/endorsing AMDD members: 26 (2017)



• Why we started it -- Distribution systems and practices in Japan





• As a result...





- Content
 - Outline of anti-corruption laws (FCPA, UK bribery act, Japan unfair competition prevention law, National public service ethics act and other local laws and regulations)
 - Case studies
 - Real case examples
 - Discussion on hypothetical cases
 - Compliance topics
 - Effective compliance program recommended under the FCPA guidelines and model company compliance policy based thereon (2014)
 - How to keep compliance program effective (management's commitment, monitoring and employee training, etc. (2015)
 - How to provide effective compliance training and practical preventive measures for corruption (2016)
 - Self-assessment for company compliance structure (2017)



• Attendees









- Learnings and challenges key to keep the program effective and efficient
 - Program generally well accepted by dealers
 - Increase the number of sponsoring companies
 - Keep the contents fresh while covering all the key points



CAPACITY BUILDING EXAMPLES: DISTRIBUTOR ETHICS TRAININGS



Recent Association Approaches

Carlos Gouvea ABIIS (Brazil)

INSTITUTO ETICASAU

ETHICS AND INTEGRITY:

SUSTAINABLE HEALTHCARE THAT CREATES VALUE


Why IES Ethics Health?



Why IES - Ethics Health?

- Environment without maturity in "transparent and ethical relationship ". Relationship was "hostile - lack of trust among the parties"
- Companies, doctors and HCPs, hospitals and HMOs/Insurance Plans were acting without clear pre-defined rules.
- Unreal consumption of Medical Devices, overindication of procedures (just as example there was a decrease in volume of over 35% after dissemination of news in the media).
- Lack of credit with the Market and with the public opinion.
- The whole cost of a "surgery" was built into the "cost of the product" (medical fees, training, hospital fees, renewal of instruments in the hospitals, surgical technicians, etc).



Why IES - Ethics Health?

- Conflicts with HMOs / Health Insurances:
 - ✓ Lack of payment
 - Postponement of the invoicing authorization
 - Financial payment denials
 - Policy of "dictating" the purchase price
 - Flattening medical fees
 - ✓ Flattening hospital fees x health plans

"ROCK BOTTOM"

It was mandatory to re-structure the whole healthcare chain or we would face the colapse of the "system"!

Who we are



ÉTICASAU





Who we are

Mechanism of self-regulation of the conduct of health actors through:

Governance Regulations and Statutes/Bylaws Prevention and Control

- ✓ Prevention: Education and Integrity Program
- ✓ **Control:** Reporting Channel





Mission

To promote the best practices in the relationships, by means of self-regulatory mechanisms for the healthcare sector.





Purposes

- To disseminate and to consolidate a culture of honesty and transparency in the healthcare sector
- ✓ Fair and healthy competition
- ✓ Access to the best technologies
- ✓ The best cost/benefit for the healthcare systems
- ✓ Appropriate availability of medical technology

And last, but not least,
The main purpose is to assure
the safety and respect to the
patient!

Values

Ethic Integrity Awareness and Education Transparency Legality







2018 APEC Business Ethics for SMEs Forum

18-20 July 2018 • Tokyo, Japan





INSTITU

Scopes of Performance





Reporting Channel

Indicators

588 Cases Reported 1446 People/Institutions

Until may 2018



Cases Reported - Main Issues

249 Concession of personal incentives, commissions for promoting the prescription of products or use of material.

56 Unfair practices to competition in public or private environment.

52 Payment to the hospital of fee or commission related to the use of materials.

42 Physician / patient relationship.

39 Practice of donating equipment or instruments in order to obtain undue advantage.

139 Members 1307 Non Members

Total: **1446**



- 652 Medical Doctors
- 461 Distributors
- 183 Hospitals
 - 81 Importers
 - 39 HMO / Health Plans
 - 21 Manufacturers
 - 6 Institutes
 - **3** Public Offices





Institutional and Government Relations

To amplify scope of action

Cooperation Agreements Advisory Board Hospitals Manufacturers

New members

HMOs / Health Insurance Companies Other segments of Medical Devices and IVDs

 InterAmerican Coalition of Ethics in the Medical Device Sector

Member of the Interamerican Coalition that gets together associations of Medical Technologies of Brazil, United States, Canada, Mexico, Argentina, Chile, Colombia, Peru, Ecuador and Venezuela.





Compliance Monitoring

- Working Groups:
 - Supply Chain
 - Hospitals
 - Risk Mapping
- Assessment of the Compliance Systems of Members (2nd Questionnaire - In 02)





Compliance Monitoring

Qualification Program IES - WualIES **Benefits**

To enable the implementation and qualification of Compliance programs

- ✓ Audit
- ✓ Consultancy

(Ernst & Young, Deloitte, PWC, KPMG, Grant Thornton)



- Protection of the Ethics Health members in hiring audit companies;
- Guarantee of compliance to a minimum \checkmark common check-list of requirements for the Medical Technology Market, promoting the most effective prevention against deviation of conduct;
- Saving time and resources; \checkmark
- Education and awareness.



Awareness and Education

Partnerships with Universities

 Online Courses (in cooperation with other entities) FEHOSP - EducaSUS

Presential Trainings

Training recognized by Industries Compliance
Systems

 Training focused on the Value Channel (Distributors) = Pilot with ABRAIDI

Annual Forum Ética Saúde

 Closed Events (CADE, ANVISA, TCU, etc.)

✓ Campaign
Ethics is not Fashion. Ethics are manners
("Ética não é moda. Ética são modos").















Carlos Eduardo Gouvêa <u>eticasaude@eticasaude.org.br</u> <u>www.eticasaude.org.br</u> Ética Saúde: 11 2640-8536 Canal de Denúncias: 0800-741-0015

Rua General Jardim, 770 – 3° andar – Conj. 3B Higienópolis – São Paulo - SP







CAPACITY BUILDING EXAMPLES: DISTRIBUTOR ETHICS TRAININGS



Pilot Webinars on the APEC Guidance

Ms. Chrisoula Nikidis Polaris (Canada)





Asia-Pacific Economic Cooperation Business Ethics for APEC SMEs Medical Device Sector SME Webinar on APEC Guidance for Ethical Third Party Intermediary Relationships in the Medical **Device Sector**

This webinar has been prepared for the Business Ethics for APEC SMEs Initiative as a contribution by: $\blacksquare QVIA^{m}$

Develop an interactive, engaging eLearning module in partnership with Polaris/IQVIA based on the Guidance for Ethical Third Party Intermediary Relationships in the Medical Device Sector



Business Ethics for APEC SMEs Medical Device Sector

Asia-Pacific Economic Cooperation



Map out strategy

- Map out eLearning module
 - Develop a story board
 - Determine the flow and pace of the eLearning presentation/module
 - Determine most appropriate format
 - Determine method of delivery

Develop Learning Objectives/Learning Outcomes

- Who are the learners completing this course?
- What do you want them to be able to do after completing the course?
- What do they need to know to do this, and
- What must the learner understand to be able to do it?

Develop Content

- Develop Content based on the Guidance for Ethical Third Party Intermediary Relationships in the Medical Device Sector
- Pilot with APEC economies
- Provide voice over



Asia-Pacific Economic Cooperation Business Ethics for APEC SMEs Medical Device Sector







Content

Introduction

- Remind learner of:
- The APEC initiative and the context in which the Guidelines were developed;
- The context of "why" 3rd Party Due Diligence is important in todays environment.

Understanding the Guidelines

- Principles and Standards summary:
- Outline the principles- Summarize each principle into one to two slides using both text and visuals followed by 1 to 2 slides that provide examples and best practices, reinforcing the understanding of the principle.

Conclusion

• Recap of material reinforcing the key points

Resources/References/Documents

- Embed links to references and resources
- Including links to articles, reference sites, and other web resources.

Contact Information



Pilot Webinars



In early July piloted the third party due diligence Webinar was piloted with two APEC Economies:

New Zealand

Canada







Economic Cooperation

Business Ethics for APEC SMEs Medical Device Sector



Recommendations for the Final version of the Webinar

- Underscore the importance and the resources that local Associations can offer;
- Stress the importance of third party due diligence and the cost of non-compliance;
- Highlight why this "Guidance applies to me" and use it as an opportunity to level the playing field;
- Provide examples of where to embed ethical third party due diligence in the current due diligence process;
- Distill principles into a template check list and action plan;
- Develop an extensive resource guide with links to global legislation, regulations, questionnaires etc.; and
- Provide contact information for embassies and trade commissions



Business Ethics for APEC SMEs Medical Device Sector



Asia-Pacific Economic Cooperation



Timelines and Roll out





Business Ethics for APEC SMEs Medical Device Sector

Asia-Pacific Economic Cooperation



CONSIDERING A "TOKYO STATEMENT" ON IMPLEMENTING THE APEC GUIDANCE FOR ETHICAL THIRD PARTY INTERMEDIARY RELATIONSHIPS IN THE MEDICAL DEVICE SECTOR

Facilitator:



Ms. Faye Sumner, MTANZ (New Zealand)



PLANNING SESSION ON IMPLEMENTATION OF APEC THIRD PARTY GUIDANCE (18 JULY) MEDICAL DEVICE SECTOR



Closing Observations

Ms. Tricia Van Orden, Project Overseer Business Ethics for APEC SMEs Initiative U.S. Department of Commerce



NETWORKING LUNCH (13:00 – 14:00)







HALF DAY SME COMPLIANCE WORKSHOP (18 JULY) MEDICAL DEVICE SECTOR



Introductory Remarks

Ms. Tricia Van Orden, Project Overseer Business Ethics for APEC SMEs Initiative U.S. Department of Commerce



HALF DAY SME COMPLIANCE WORKSHOP (18 JULY) MEDICAL DEVICE SECTOR





Ms. Zohra Anwari, Legal Counsel The Advanced Medical Technology Association



HALF DAY SME COMPLIANCE WORKSHOP (18 JULY) MEDICAL DEVICE SECTOR

Participant Introductions

NAME | POSITION | ORGANIZATION | ECONOMY


HALF DAY SME COMPLIANCE WORKSHOP (18 JULY) MEDICAL DEVICE SECTOR

Panel: Spotting Global Compliance Trends for SMEs and Understanding Risks

MODERATOR:



Ms. Zohra Anwari AdvaMed



Ms. Angela Main Zimmer Biomet



Ms. Caroline West Olympus Corporation



Ms. Joyce Wong Polaris



SHORT PRESENTATIONS ON ORGANIZING YOUR COMPLIANCE PROGRAM TO SUPPORT YOUR COMPANY'S GROWTH



Structuring your Compliance Program

Ms. Tamara Olmos AMID (Mexico)





To promote progress of health services in Mexico through the access to medical advances, improving the quality of people's life.



SMALL & MEDIUM COMPANIES: OUR REALITY





STRUCTURING YOUR COMPLIANCE PROGRAM





ACTIONS TAKEN

Trainings

Co-responsibility of distributors by contract

Monitoring and auditing



GETTING CLOSER TO YOUR DISTRIBUTORS THROUGH YOUR ASSOCIATION

C

1

- ✓ Code of Interaction w/ HCP's
- End of direct sponsorships notice
- ✓ Q&A
- ✓ 3 minutes video (FB, LinkedIn, Twitter, Website)





HOW A COMPLIANCE PROGRAM MAKES YOUR COMPANY GROW

+ Regulation **Transparency** Antitrust system Put money Compliance where really matters program Fair play



"Compliance is not a waste of money, it's a necessary investment if you want your Company to succeed".





SHORT PRESENTATIONS ON ORGANIZING YOUR COMPLIANCE PROGRAM TO SUPPORT YOUR COMPANY'S GROWTH

Training, Metrics, Auditing & Monitoring



Mr. Wes Porter Wright Medical (The United States)



Mr. Emmanuel Vicencio Wright Medical (The United States)



Agenda

- Developing an Audit, Monitoring, and Training Program
 - Risk Assessment
 - Project Plan Audit & Monitoring
 - Training Program
- Final Thoughts



Developing an Audit, Monitoring, and Training Program

- Risk Assessment
 - Priority
 - Metrics
 - Change Management
- Project Plan
 - Audit Projects
 - Monitoring Activities
- Training Program
 - Policies/Procedures
 - Applicable Laws/Risks





Risk Assessment

- Identify risk areas.
 - Interviews with Company Leaders
 - Use of Metrics/Financial Data
- Results utilized to develop the Compliance Project Plan.





Audit

- Projects designed to review a specific activity or risk areas.
- Audit projects may include:
 - Global Anti-Bribery/Anti-Corruption Reviews
 - Third Party Intermediary Reviews
 - Process Reviews
 - Special Projects





Monitoring

- Activities/tasks that are continuous and measured.
- Monitoring may include:
 - Metrics/Analytics
 - Change Management/ Environment





Training

- Avenue to communicate policies and any applicable laws.
 - Delivered electronically or in person.
 - New hires globally
 - Company representatives
 - Consider Audit & Monitoring results.





Final Thoughts

- The Risk Assessment is the starting point for developing a Project Plan.
- The Audit Plan addresses risks and includes an effective monitoring of activities to identify on-going potential risks.
- A Compliance Training program includes major risks or control weaknesses.





SHORT PRESENTATIONS ON ORGANIZING YOUR COMPLIANCE PROGRAM TO SUPPORT YOUR COMPANY'S GROWTH



<u>Association Tools & Resources/Benefits of</u> <u>Association Codes</u>

Ms. Michelle Wagner MTAA (Australia)



Association Tools & Resources / Benefits of Association Codes

Michelle Wagner Member, MTAA Code Authority

Health Care Compliance Sector Lead, Medical Devices Asia Pacific Johnson & Johnson Health Care Compliance & Privacy

Johnson & Johnson Medical



About MTAA

The Medical Technology Association of Australia (MTAA) is the peak association representing over 100 medical technology industry members from across the country.

MTAA aims to ensure the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community.



Strategic areas of activities

The MTAA Strategic Plan 2017-2020 prioritises work in five strategic areas











Code Review

- The Code of Practice 9th Edition 2015 current
- The Code is reviewed every 3 years
- An administrative review of the Code of Practice is currently underway
- Principle changes and Edition 10 of the Code is expected end of 2018/early 2019



Benefits of an Association Code

- The MTI Code demonstrates members' proactive commitment to high standards of ethical behaviour - as an industry and as individual companies
 Ethical Leadership
- Self regulatory
- Robust processes that include independent experts, consumer representatives and HCPs
- Industry maintains input into the Code and the administrative processes provides flexibility to update/improve as necessary



Benefits of an Association Code





Governance of the MTI Code





Code Monitoring - Committee Structure

MTTAA has two Code Committee Structures:

- Code Authority Committee oversight and effective administration of the Code
- Code Monitoring Committee reviews monitoring reports
 from member companies
- To provide consistency, The Chair is the same for both Committees



Monitoring - Reporting Topics & Administration

- Member companies are asked to report on how they ensure internal compliance and to provide distributed comparative advertisements and competitions held within the reporting period
- The monitoring process is conducted as set out on the next slide



Monitoring Process

Collection

MTAA collects monitoring reports from each member once per annum

MTAA checks reports have been filled correctly and follow up if necessary prior to meeting

MTAA sends monitoring reports to CMC 2 weeks prior to review meeting

Review Meeting

For each report reviewed, the CMC agrees on the appropriate decision of either compliant, a follow-up is required or a potential breach of the Code

For each follow up or potential breach the CMC agrees on the content of and questions to be raised with the company

Post Meeting

A report of the meeting is drafted for publishing to committee members

MTAA carries out actions with each member in accordance with CMC decisions

Additional information is provided back to CMC to determine compliance

Reporting

Chair to provide updates to the Code Authority

MTAA records statistics each year for annual reporting

Quarterly report is published to committee members on monitoring activities.



MTAA Education and Training

- The Code of Practice is the overarching governance that ensures MTAA Members adhere to strong ethical practices and ensure compliance through the provisions of the Code
- This is achieved through ongoing education and training, monitoring of compliance and dedicated Committee meetings and forums
- Non-member Medical Device companies are also strongly encouraged to comply with the Code



MTAA Education and Training

- The online Code of Practice training is free for all employees of our members
- For non-members, the Code of Practice training is \$99
- Currently, 2484 employees predominately from member companies have completed the online Code of Practice E9 training since the revision of the Code in 2015
- The online training includes hypothetical scenarios for members to complete based on the context of each clause in the Code
- MTAA are currently revising the face to face training offered to members



Ongoing Advice and Information for Members

- The MTAA website includes a FAQs section, the content within this section is derived from queries received from members
- Enquiries received from members include the interpretation and clarification of the clauses and provisions of the Code
- Common enquiries received from members include questions and clarification surrounding advertising, branding and gifts



THE POSITIVE OUTCOMES OF AN ETHICAL CULTURE: WHY THIS MATTERS TO INVESTORS AND ENTERPRISE SUCCESS



Ms. Diane Biagianti Vice President, Chief Responsibility Officer Edwards Lifesciences



NETWORKING TEA (16:30-16:45)







ISSUE SPECIFIC CASE STUDIES VIA 45 MINUTE ROTATING BREAKOUT SESSIONS





FACILITATOR: Ms. Patricia Wu, Managing Director, C&M International (Technical Secretariat)

SPONSORSHIPS *Mr.* Campbell Clark, *Medtronic,* Singapore





VALUE-ADDS/TENDERS/ CONFLICTS OF INTEREST AND PROCUREMENT Mr. Rhoel Laderas, PAMDRAP, Philippines


CASE STUDY TWO: CONFERENCE VENUE



CASE OVERVIEW:

- JPMed Corp (JPM) is a Japanese company, a member of an industry association, and is planning promotional events for healthcare professionals.
- JPM is considering an island resort hotel as the conference venue.
- JPM is planning a dinner cruise for the healthcare professionals coming to the island and marine activities for them after the conference.
- JPM's industry association has a code of ethics, which mentions "no excessive offers to healthcare professionals" but does not provide venue guidelines.
- JPM has order the conference leaflet.



The 1st Med-Forum, Sunny Island 18-20 July 2018

Presented by **JPMed**

Time Table

	Day 1 18 Jul.	Day 2 19 Jul.	Day 3 20 Jul.
9:00-12:00	Introduction / Key note speech	Hands-On 2	Excursion at the beach with
12:00-13:00	Lunch	Lunch	lunch buffet
13:00-17:00	Hands-On 1	Discussion / Wrap up	Go to airport
18:00-	Reception Dinner	Cruise Dinner	



Case Study # 3: Financial Transparency

Financial transparency is of paramount importance when Healthcare Companies deal with Healthcare Professionals. Companies should always be on the look out for potential conflicts of interests and or "red flags' when conducting business relations with key decision makers who can also be the company's contracted resource. Efforts must also be made to prove/show that scientific engagements with HCPs are focused on professional learning and not a means to broaden business opportunities within the HCPs scope of influence.



Scenario:

Apex Hospital is a family owned corporation managed by Dr. Phil, a practicing Cardiologist. Dr. Phil co-owns the hospital with his siblings and has a 20% stake in the company. He is concurrently the Head of the hospital's Cardiology Department.

In July 2017, he was invited a Clinical Research Organization (CRO) ClinMax to be the principal investigator for a major clinical study for an improved artificial heart valve manufactured by ValveX. The study will be conducted in Apex hospital and was pre selected by its clinical study sponsor, ValveX as one of 3 clinical study sites in the country.

While negotiations were ongoing for the clinical study, a ValveX Sales Manager Mike A approaches the purchasing department to offer their Artificial Pacemaker to the hospital. The ValveX pacemaker offers some distinct advantage over the currently used device in the hospital. He conducts product presentations and trainings to hospital staff for product appreciation. Per internal purchasing process, final approval any department related purchase orders is the Department Head.

Two months after the Clinical Trial contracts were signed and approved by the hospital, Mike A was able to close a supply agreement with Apex Hospital covering a period of 3 years.



Analysis/Questions:

- What do you think are the red flags in this scenario?
- How can Dr. Phil better manage his role as a consultant and a customer?
- How can ValveX avoid the perception that utilizing the scientific relationship with

Dr. Phil was a means to expand business opportunities within Apex Hospital?



CONCLUDING SESSION AND PREVIEW OF TOMORROW



Ms. Zohra Anwari, Legal Counsel The Advanced Medical Technology Association







MULTI-STAKEHOLDER TRAINING WORKSHOP (19 JULY) MEDICAL DEVICE SECTOR



Introductory Remarks

Ms. Tricia Van Orden, Project Overseer Business Ethics for APEC SMEs Initiative U.S. Department of Commerce



MULTI-STAKEHOLDER TRAINING WORKSHOP (19 JULY) MEDICAL DEVICE SECTOR

Participant Introductions

NAME | POSITION | ORGANIZATION | ECONOMY







LEVERAGING TECHNOLOGY AND OTHER RESOURCES TO SCALE CODE OF ETHICS IMPLEMENTATION FOR SMES

PRESENTERS



Ms. Stephanie Chew AdvaMed China



Ms. Minah Cho KMDIA Korea



Ms. Fara Zalina Mohamed SME Corp Malaysia







"Leveraging Technologies and Other Resources to Scale Code of Ethics Implementation for SMEs" A Public Sector Perspective

19 July 2018





Barriers (AdvaMed China)

- Lack of resources such as funding for human resources and technologies
- Hard to attract members (HCPs, Distributors or local manufacturers)
- Government or other healthcare institution policies may not be of the same high standards
- Lack of consequences for not adopting or breaching the code
- Uneven level playing field





Heighten prioritization of code implementation from large company perspective

Internally

- Build a culture of ethics and compliance Do the Right Thing!
- Lead by requiring TPI engaged comply with ethical code
- Sponsor, support and participate in industry ethics initiatives (certify the adoption of the code).

Externally

- Lobby with government (through association) to provide preference treatment for companies who have under taken higher ethics & integrity standards. (e.g. enforcement or procurement)
- Encourage government to "punish" the demand side
- Influence HCPs to comply with the law and code of ethics





How Korea Medical Device Associations to leverage *Technologies* for companies to implement Code of Conduct or Government requirement ?



Code of Conduct Reporting System

- Set up the Code of Conduct Reporting System for companies easy access from 2013 for Pre- Post Reporting Requirement based on CoC
 - Sponsoring Overseas symposium , Sponsoring 3rd party event, Product Presentation with Multi hospital , Speaker & Consultation engagement, Market research , Exhibition ,

Advertisement , Donation and Product Training

• In 2017 More than 7, 000 were submitted





Expense Reporting System

- KMDIA codeveloped system for SMEs
- Medical device companies are required to establish and maintain an expense reporting system to collect and report on economic benefits provided to HCPs based on transparency ACT from 2018 Jan.1
 - samples , clinical trials, post market surveillance , product presentations, academic conference, prices discount based on payment conditoins and demo evaluation

Fair Pay MeD							을 로그아운
017년 10월 15월자 전자세금계산 ♥ ♥ ♥	지출보고	7]출보고&공정경쟁	공정경쟁	자사관리	알림마당	
지출보고				공정경쟁			مۍ
구분	신정변호	등록일	질지상태	구분	신정변호	등록멅	경제상태
의료기기사용	SAM1711-001	2017-11-07	승민요청	작술대희운영	ACD/1705-005-01	2017-11-07	승민요정
의료기기사용	SAM1711-002	2017-11-07	반려	학술대회운영	ACD/1705-005-01	2017-11-07	반려
의료기기사용	SAM1711-003	2017-11-07	승민완료	작술대희운영	ACD/1705-005-01	2017-11-07	승민완료
의료기기사용	SAM1711-004	2017-11-07	승민취소	작술대희운영	ACD/1705-005-01	2017-11-07	승인취소
의료기기사용	SAM1711-005	2017-11-07	승민완료	작술대회운영	ACD/1705-005-01	2017-11-07	승민완료
공지사항			More +	FAQ			More +
· 관세정 천산장애로 인한 송수신 지연 🚥		17.11.05	 신규등복품룩과 최근식제품룩을 확인할 수 있나요? 				
 [공지] 화장품 표준통관여정보고(원료폭록보고) 업무관련 주가 안 		17.10.31	 오류동브 메뉴를 클릭해도 자세한 내용이 나오지 않네요 				
· "화장쭓수입무떡관리 설명회 개최"		17.10.30	 나탄의 정보수첩 메뉴의 주소록 텦 메일보내기는 어떤 기능인가요? 				
 [공지] 한국의약품수를입협회 민뤈업무 처리 안내 17.10. 		17.10.24	 대협업체에 통관애정보고서 업무를 위탁한경우 메디코리아의 별도 가입 절자가 있는 				
· [풍지] 웹시공휴일 및 휴무 안내 17.09.24			 자동이체 신경 후 정상적으로 사용요금이 자동민출 되었는데 Medikorea에 로그면서 				

시스템 메인 화면



Malaysian Perspective





Good Business Perspective











Ethics Implementation





Ethics Awareness

Efforts to promote the importance of Business Ethics





SME Corp. Malaysia





How can APEC economies and governments create "enablers" for high-standard ethical *business* practices?



Asia-Pacific Economic Cooperation





EXERCISE ON STRATEGIES TO SCALE CODE OF ETHICS IMPLEMENTATION FOR SMES

Facilitators



Mr. Thomas Hsu Edwards Lifesciences



Ms. Tamara Tubin Wright Medical



MEDICAL DEVICE SECTOR MULTI-STAKEHOLDER TRAINING WORKSHOP (19th July 2018) Leveraging Technologies to Scale Code of Ethics Implementation for SME's

Manhattan Room Three, Tokyo American Club, 2-1-2 Azabudai, Minato-ku, 106-8649 Tokyo, Japan

11:00 – 12:00 Exercise on Strategies to Scale Code of Ethics Implementation for SMEs

Facilitators: Mr. Thomas Hsu, Edwards Lifesciences, Ms. Tamara Tubin, Wright Medical

Objective: This exercise will focus on strategies that SMEs may develop for the scaling of Code of Ethics implementation.

This exercise shall help i) identifying possible challenges and ii) how to remove barriers in order to be successful and effective.



Proposed Timeline

11:00 – 11:05 Brief Introduction of Facilitators.

11:05 – 11:10 Objective & Introduction of the Workshop.

11:10 - 11:40

- Groups to be created for the workshop.
- Quick individual introduction around the tables.
- Appointment of a leader to present during the outcome session.
- Start exercise.
- Facilitators to facilitate.

11:40 – 11:55 Each group's leader to present

11:55 - 12:00 Conclusion and Closing



NETWORKING LUNCH (12:00-13:00)







STRATEGIES FOR SUCCESS ON IMPLEMENTING THE APEC GUIDANCE FOR ETHICAL THIRD PARTY INTERMEDIARY RELATIONSHIPS

FACILITATORS



Ms. Faye Sumner MTANZ New Zealand



Ms. Stephanie Chew Medtronic China



Mr. Ronald Goon Johnson & Johnson Singapore



Guidance for Ethical Third Party Intermediary Relationships

- A. Written Anti-Bribery Policy/Procedure
- B. Risk Assessment
 - I. Companies
 - II. Third Party SMIs
- C. Diligence Program
- D. Written Contract
- E. Training and Education
- F. Monitor/Audit
- G. Appropriate Corrective Action



Implementation

- Stakeholders: Industry associations, Company employees, Third Party SMIs (Distributors, Marketing Agents, etc.), HCPs, Government authorities
- Implementing codes of ethics consistent with the principles set out above and <u>additional</u> <u>steps</u> to encourage the adoption of this guidance among their respective members and/or employees;
- Encouraging the development and implementation of high-standard, <u>aligned policies and</u> practices consistent with this guidance;
- Undertaking joint communication and training on this guidance and other relevant policies;
- Encouraging medical device sector <u>regulators and enforcement authorities to acknowledge</u> and <u>support the guidance</u>, and to support steps by stakeholders to implement effective guidance for ethical Third Party SMI relationships; and
- Encouraging APEC economies to advance ethical collaborations consistent with this guidance, through regular communication, joint policies, joint capacity building, and other forms of collaboration.



Exercise

- Group 1 Written Anti-Bribery Policy/Procedure & Written Contract
- Group 2 Risk Assessment
- Group 3 Diligence Program
- Group 4 Training and Education
- Group 5 Monitor/Audit & Appropriate Corrective Action

✓ Assign a table lead (who do not rotate and will report out)

✓ Team members to rotate to another table after 20 min discussion

✓ Report Out (5 min per group)



Discussion questions

- What are the 3 keys priorities to implement or execute the elements?
- What are the resources needed?
- What are the potential challenges and propose potential solutions?






INTERACTIVE, MULTI-STAKEHOLDER CASE STUDIES

14:30-16:45

LEAD FACILITATOR



Mr. Adrian Cosenza, Chief Executive Officer Australian Orthopaedic Association





MENTOR TEAM INTRODUCTIONS

Ms. Michelle Wagner Compliance Lead Medical Devices, Johnson & Johnson Medical Technology Association of Australia



Ms. Ana Garcia Bello Vice President – Law, Medical Devices Group, Asia-Pacific Johnson & Johnson





MENTOR TEAM INTRODUCTIONS

Ms. Charlotte Tan Sr. Director, Group Compliance Officer, Asia-Pacific Stryker Corporation



Mr. Kei Matsumoto General Manager, Compliance Dept. Olympus Corporation The Japan Federation of Medical Device Association



INTERACTIVE, MULTI-STAKEHOLDER CASE STUDIES 14:30-16:45

Session One 14:30-15:30

Case Study One: Consulting arrangements with HCP's

Networking Tea Coffee Break 15:30-15:45

Session Two 15:45-16:45

Case Study Two: Sponsorships

Case Study Three: Research



The Kuala Lumpur Principles Medical Device Sector Code of Ethics

- Integrity means dealing honestly, truthfully and fairly with all parties
- Independence means that HCP interactions with companies should not skew the HCP's medical decision making from the best interests of the patient
- <u>Appropriateness</u> means that arrangements conform to proper commercial standards, and are accurate and free from corrupt purposes
- <u>Transparency</u> means that companies and HCP's are open regarding significant financial relationships between the parties
- <u>Advancement</u> means that relationships are intended to advance medical technology innovation and patient care



Strengthening Ethical Interactions

- **Industry Associations**
- **Medical Device Companies**
- Healthcare Professionals
- Healthcare Professional Associations
- Patients
- Hospitals
- Regulators



2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan

<u>CASE STUDY ONE:</u> <u>CONSULTING RELATIONSHIPS WITH HCPS</u>



Key Players - Role Play

Industry Association – Head of Legal & Compliance Committee - Ana

<u>Medical Device Company</u> – RTS Eye Health Pty Ltd-Marketing Director - **Charlotte**

<u>Healthcare Professional</u> - Dr Flowers Opthalmologist -**Michelle**

Healthcare Professional Association – College of Opthalmologists

Patient - Adrian



KEY QUESTIONS:

- Discuss each of the services planned for Dr Flowers and determine if they would meet the requirements of the Code.
- Would each of these interactions appear ethical to patients in Japan and the US and why or why not?
- If you are Dr Flowers what considerations would you give to this proposal and could you commit to this contract with RTS?
- If you are the Compliance Officer at RTS, what advice would you give RTS about the planned activities and consultancy arrangement?



2018 APEC Business Ethics for SMEs Forum 18-20 July 2018 • Tokyo, Japan

NETWORKING TEA (15:30-15:45)



CASE STUDIES TWO & THREE: SPONSORSHIPS and RESEARCH



The Kuala Lumpur Principles Medical Device Sector Code of Ethics

- Integrity means dealing honestly, truthfully and fairly with all parties
- Independence means that HCP interactions with companies should not skew the HCP's medical decision making from the best interests of the patient
- <u>Appropriateness</u> means that arrangements conform to proper commercial standards, and are accurate and free from corrupt purposes
- <u>Transparency</u> means that companies and HCP's are open regarding significant financial relationships between the parties
- <u>Advancement</u> means that relationships are intended to advance medical technology innovation and patient care



Strengthening Ethical Interactions

- **Industry Associations**
- **Medical Device Companies**
- Healthcare Professional Leaders
- Healthcare Professional Associations
- Patients
- Professional Conference Organisers



CASE STUDY TWO : SPONSORSHIPS

- Dr. Jones, an experienced and generally well known medical professional from the United Kingdom would like to attend a third party educational congress in Thailand, Thai Hip and Knee Society Annual Meeting (THKS).
- Dr. Jones is a strong supporter of your company and currently has a consulting agreement with your company to teach other surgeons in the use of your products.
- The THKS event will be held at a beach resort commonly used for large meetings. The scientific and educational value of the event has been assessed to be adequate. Your company has decided to have a booth at the event.



CASE STUDY TWO : SPONSORSHIPS

- Your sales representative suggested the following:
 - Organize a company training event 1-2 days before the congress in Thailand and invite Dr. Jones as the faculty speaker/trainer. This will enable your company to sponsor his travel costs from the United Kingdom to Thailand.
 - Provide a grant to the Thai Hip and Knee Society and informally advise that the grant is for Dr. Jones' registration and accommodation at the congress.
 - Thai Hip and Knee Society provides Dr. Jones with accommodation during the THKS as part of his faculty arrangement.



KEY QUESTIONS:

- Are there any challenges with the proposal by the sales representative?
- Assuming the local industry code prohibits direct HCP sponsorship, what controls can be implemented to detect attempts to circumvent the prohibition of providing direct sponsorship?



CASE STUDY THREE : RESEARCH

A large university hospital in Tokyo and is seeking funding for its research. The university has requested ABC Limited (a medical device company) to support a number of its research projects as follows:

- Scholarship fund 10,000,000 JPY The prospectus reads that the funding will be used for any and all research related to surgery. No details on each research is provided. The University have asked ABC Limited, as a market leader, to support 70%.
- The university is celebrating their 90th anniversary and they have requested funding for their memorial project. The project includes renovation of the research facilities and the department of medicine's building, construction of a new clinic, and installation of a garden in their affiliated hospital. Funding breakdown is 30% for university and 70% for clinic/hospital.



CASE STUDY THREE : RESEARCH

The University have advised ABC Limited that if the support is not provided, their products will be "subject for reconsideration on its continuous usage" at their affiliated hospitals in Japan.

The Industry Association Code requires that the research needs to be on specific theme in order to avoid funds to be utilised for operational /management cost. In addition, research funding requires a report at the end from the requester to explain the summary of the research and usage of fund. Grants cannot be supported if:

- The research does not contain highly professional and sophisticated subjects on medicine and medical devices beyond the normal medical practice
- The support is excessive compared to other companies
- The support is allocated and forced
- Used to induce or maintain sales



KEY QUESTION

You are the Compliance Officer for ABC Limited. Consider the above scenario and provide your advice to ABC management as to whether it complies with the Code, whether the support would be considered ethical to the public and your reasons. If the company proceeds with the support, what would vou recommend they require for documentation.



The Kuala Lumpur Principles Medical Device Sector Code of Ethics

- Integrity means dealing honestly, truthfully and fairly with all parties
- Independence means that HCP interactions with companies should not skew the HCP's medical decision making from the best interests of the patient
- <u>Appropriateness</u> means that arrangements conform to proper commercial standards, and are accurate and free from corrupt purposes
- <u>Transparency</u> means that companies and HCP's are open regarding significant financial relationships between the parties
- <u>Advancement</u> means that relationships are intended to advance medical technology innovation and patient care



GUIDANCE FOR PLENARY (20 JULY)



Ms. Patricia Wu Managing Director C&M International